Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease (AFIRE)
EBM, Journal Club
Thank you Nikita for leading us through a discussion of the AFIRE trial.
Clinical Question:
In patients with atrial fibrillation and stable CAD >1 year after revascularization (or confirmed CAD on angiography not requiring revascularization), how does rivaroxaban monotherapy compare to rivaroxaban plus an antiplatelet agent in terms of efficacy and safety?